Why Study FoxP3?
FoxP3-positive lymphocytes are commonly associated with regulatory T-cell activity and immune suppression. Although several studies have examined FoxP3 in pancreatic cancer, most evaluated it as a single measurement without considering where these immune cells were located.
We hypothesized that the biological significance of FoxP3-positive lymphocytes might depend on their spatial distribution within the tumor microenvironment.
To investigate this question, we analyzed 98 surgically resected PDAC cases and separately assessed FoxP3 expression in three distinct compartments:
- Intratumoral (IT)
- Peritumoral (PT)
- Tumor-associated stromal (T)
This compartment-based approach enabled a more detailed characterization of the immune landscape surrounding pancreatic cancer.
High FoxP3 Expression Predicts Poorer Overall Survival
One of the most striking findings of our study was the consistent association between elevated FoxP3 expression and reduced overall survival.
Across all evaluated compartments, patients with high FoxP3 expression demonstrated significantly shorter overall survival than those with low expression.
These findings suggest that immunosuppressive immune populations contribute to aggressive tumor behavior regardless of their precise anatomical location.
High FoxP3 Expression Also Predicts Earlier Recurrence
Overall survival represents only one aspect of clinical outcome. We therefore evaluated disease-free survival to determine whether FoxP3-positive lymphocytes were also associated with tumor recurrence.
Patients exhibiting higher FoxP3 expression experienced earlier recurrence following surgical resection. This finding suggests that FoxP3-associated immune suppression may influence not only mortality but also mechanisms driving disease progression and relapse.
Prognostic Effects Persist in Patients Receiving Adjuvant Therapy
An important question was whether FoxP3 retained prognostic significance among patients receiving postoperative chemotherapy.
Interestingly, compartment-specific FoxP3 expression remained associated with survival outcomes even within this clinically important subgroup. These findings support the robustness of spatial immune profiling and suggest that FoxP3-related biology may remain relevant despite systemic treatment.
Why Spatial Pathology Matters
Traditional pathology has always relied on spatial information. Pathologists routinely evaluate tumor invasion, lymphovascular invasion, surgical margins, and many other features based on anatomical relationships.
Our findings suggest that immune biomarkers should be approached similarly.
Rather than simply determining whether immune cells are present, future pathology workflows may increasingly focus on where these cells are located and how they interact with surrounding structures.
Advances in digital pathology, artificial intelligence, multiplex imaging, and spatial transcriptomics may further enhance our ability to characterize these complex relationships.
Key Findings
🔬 98 resected PDAC patients were evaluated.
📍 FoxP3-positive lymphocytes were assessed separately in intratumoral, peritumoral, and stromal compartments.
📈 High FoxP3 expression predicted significantly shorter overall survival.
📉 High FoxP3 expression predicted shorter disease-free survival.
🧬 Spatial localization provided clinically meaningful prognostic information.
🚀 Spatial pathology approaches may improve future biomarker development and personalized treatment strategies.
Citation
Kandemir H, Solakoglu Kahraman D, Aktas S, Unal OU, Cagiral S. Spatially Resolved FoxP3 Positive Lymphocyte Infiltration Within the Tumor Microenvironment Predicts Survival in Resected Pancreatic Ductal Adenocarcinoma. Discover Oncology. 2026. DOI: 10.1007/s12672-026-05195-7